2 Information about pembrolizumab

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, MSD) as monotherapy is indicated for treating high microsatellite instability (MSI) or mismatch repair (MMR) deficient tumours in adults with:

  • 'unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy'

  • 'advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation'

  • 'unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.


2.3 The list price is £2,630.00 for a 25 mg per 1 ml concentrate for solution for infusion vial (excluding VAT; BNF online accessed June 2023).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)